Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
IRWD Stock Forecast 2026-2027
$3.87
Current Price
$637.05M
Market Cap
Buy 2
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to IRWD Price Targets
+158.4%
To High Target of $10.00
+38.2%
To Median Target of $5.35
-4.4%
To Low Target of $3.70
IRWD Price Momentum
-13.4%
1 Week Change
+9.9%
1 Month Change
+389.9%
1 Year Change
+14.8%
Year-to-Date Change
-33.0%
From 52W High of $5.78
+460.9%
From 52W Low of $0.69
📊 TOP ANALYST CALLS
Did IRWD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Ironwood is one of their latest high-conviction picks.
Latest IRWD Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, IRWD has a neutral consensus with a median price target of $5.35 (ranging from $3.70 to $10.00). The overall analyst rating is Buy (7.5/10). Currently trading at $3.87, the median forecast implies a 38.2% upside. This outlook is supported by 2 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jason N. Butler at Citizens, projecting a 158.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IRWD Analyst Ratings
2
Buy
2
Hold
0
Sell
IRWD Price Target Range
Low
$3.70
Average
$5.35
High
$10.00
Current: $3.87
Latest IRWD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IRWD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 26, 2026 | Citizens | Jason N. Butler | Market Outperform | Maintains | $10.00 |
| Jan 5, 2026 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Jan 5, 2026 | Citizens | Market Outperform | Upgrade | $N/A | |
| Nov 11, 2025 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Apr 15, 2025 | Wells Fargo | Equal-Weight | Downgrade | $N/A | |
| Apr 15, 2025 | Jefferies | Hold | Downgrade | $N/A | |
| Apr 14, 2025 | Leerink Partners | Market Perform | Maintains | $N/A | |
| Jan 30, 2025 | JMP Securities | Market Outperform | Maintains | $N/A | |
| Jan 22, 2025 | Craig-Hallum | Buy | Maintains | $N/A | |
| Sep 9, 2024 | Leerink Partners | Market Perform | Initiates | $N/A | |
| Aug 9, 2024 | Wells Fargo | Overweight | Maintains | $N/A | |
| Aug 9, 2024 | Craig-Hallum | Buy | Maintains | $N/A | |
| May 10, 2024 | Craig-Hallum | Buy | Maintains | $N/A | |
| Mar 1, 2024 | Wells Fargo | Overweight | Maintains | $N/A | |
| Feb 16, 2024 | Piper Sandler | Overweight | Maintains | $N/A | |
| Jan 17, 2024 | Craig-Hallum | Buy | Initiates | $N/A | |
| Dec 14, 2023 | Wells Fargo | Overweight | Initiates | $N/A | |
| Sep 28, 2023 | JMP Securities | Market Outperform | Initiates | $N/A | |
| May 23, 2023 | Piper Sandler | Overweight | Maintains | $N/A | |
| Aug 29, 2022 | Piper Sandler | Overweight | Initiates | $N/A |
Ironwood Pharmaceuticals Inc. (IRWD) Competitors
The following stocks are similar to Ironwood based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Ironwood Pharmaceuticals Inc. (IRWD) Financial Data
Ironwood Pharmaceuticals Inc. has a market capitalization of $637.05M with a P/E ratio of 6.2x. The company generates $361.51M in trailing twelve-month revenue with a 28.3% profit margin.
Revenue growth is +158.9% quarter-over-quarter, while maintaining an operating margin of +68.1% and return on equity of -9.2%.
Valuation Metrics
Market Cap
$637.05M
Enterprise Value
$1.04B
P/E Ratio
6.2x
PEG Ratio
0.0x
Price/Sales
1.8x
Growth & Margins
Revenue Growth (YoY)
+158.9%
Gross Margin
N/A
Operating Margin
+68.1%
Net Margin
+28.3%
EPS Growth
+158.9%
Financial Health
Cash/Price Ratio
+34.6%
Current Ratio
1.4x
Debt/Equity
-2.8x
ROE
-9.2%
ROA
+33.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Ironwood Pharmaceuticals Inc. (IRWD) Business Model
About Ironwood Pharmaceuticals Inc.
What They Do
Develops and commercializes gastrointestinal drugs.
Business Model
Ironwood Pharmaceuticals generates revenue primarily through the sale of its flagship drug, linaclotide (Linzess), targeting gastrointestinal conditions such as IBS-C and CIC. The company also pursues strategic partnerships to bolster drug development and expand its market presence, enhancing its profitability and growth potential.
Additional Information
Based in Cambridge, Massachusetts, Ironwood is committed to addressing unmet medical needs in the gastrointestinal sector. Its focus on innovative research and collaborations positions it as a significant player in the biotechnology industry, with goals to improve patient outcomes and healthcare experiences globally.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
100
CEO
Mr. Thomas A. McCourt
Country
United States
IPO Year
2010
Website
ironwoodpharma.comIronwood Pharmaceuticals Inc. (IRWD) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
UnitedHealth Tops Q2 Earnings on Cost Control, Raises '26 Outlook
UNH beats Q2 earnings estimates on lower medical costs and stronger Optum Insight, then raises its 2026 EPS and cash flow outlook.
Jul 16, 2026
By Zacks Equity Research
Analyst Blog
BioCryst (BCRX) Surges 8.1%: Is This an Indication of Further Gains?
BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Jul 08, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Zacks Style Scores can help investors identify strong, market-beating stocks for their portfolios.
Why It Matters
Zacks Style Scores can guide investors in selecting stocks with potential for strong performance, enhancing portfolio returns and minimizing risk.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Ironwood Pharmaceuticals announced the retirement of CMO Dr. Michael Shetzline and appointed Dr. Jeffrey Silber as his successor to oversee Research, Drug Development, and related areas.
Why It Matters
Leadership changes can impact a company's strategic direction and development pipeline, potentially influencing stock performance and investor sentiment in the biotech sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
COLL, IRWD, AMTB, and DUK are highlighted as defensive stock picks as investors shift from AI tech to safer sectors during the current market sell-off.
Why It Matters
Shifts to defensive stocks like COLL, IRWD, AMTB, and DUK indicate a move towards stability, suggesting potential volatility in tech and a focus on safer investments.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Indivior, Aurinia, Ironwood, Altimmune, and Marker are featured in an Industry Outlook article, indicating their relevance in the current market landscape.
Why It Matters
The mention of Indivior, Aurinia, Ironwood, Altimmune, and Marker signals potential market opportunities or risks, impacting stock performance and investment strategies in the healthcare sector.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
The Zacks Medical-Drugs industry is experiencing significant innovation. Stocks INDV, AUPH, IRWD, ALT, and MRKR are recommended as potential portfolio additions.
Why It Matters
Peak innovation in the Zacks Medical-Drugs industry suggests strong growth potential for companies like INDV, AUPH, IRWD, ALT, and MRKR, indicating favorable investment opportunities.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Ironwood anticipates strong revenue and profit growth in 2026 for Linzess, driven by high demand, a pediatric expansion, and pricing adjustments.
Why It Matters
Ironwood's anticipated revenue and profit growth from Linzess due to strong demand, pediatric expansion, and pricing changes signal potential for increased shareholder value and market confidence.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About IRWD Stock
What is Ironwood Pharmaceuticals Inc.'s (IRWD) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, Ironwood Pharmaceuticals Inc. (IRWD) has a median price target of $5.35. The highest price target is $10.00 and the lowest is $3.70.
Is IRWD stock a good investment in 2027?
According to current analyst ratings, IRWD has 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.87. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IRWD stock?
Wall Street analysts predict IRWD stock could reach $5.35 in the next 12 months. This represents a 38.2% increase from the current price of $3.87. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Ironwood Pharmaceuticals Inc.'s business model?
Ironwood Pharmaceuticals generates revenue primarily through the sale of its flagship drug, linaclotide (Linzess), targeting gastrointestinal conditions such as IBS-C and CIC. The company also pursues strategic partnerships to bolster drug development and expand its market presence, enhancing its profitability and growth potential.
What is the highest forecasted price for IRWD Ironwood Pharmaceuticals Inc.?
The highest price target for IRWD is $10.00 from Jason N. Butler at Citizens, which represents a 158.4% increase from the current price of $3.87.
What is the lowest forecasted price for IRWD Ironwood Pharmaceuticals Inc.?
The lowest price target for IRWD is $3.70 from at , which represents a -4.4% decrease from the current price of $3.87.
What is the overall IRWD consensus from analysts for Ironwood Pharmaceuticals Inc.?
The overall analyst consensus for IRWD is neutral. Out of 2 Wall Street analysts, 2 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $5.35.
How accurate are IRWD stock price projections?
Stock price projections, including those for Ironwood Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 2:44 AM UTC